Pharmacological modulation of myocardial tumor necrosis factor α production by phosphodiesterase inhibitors

Journal of Pharmacology and Experimental Therapeutics

Volumn 279, Issue 1, 1996, Pages 247-254

  Bergman, Marina R ^a   Holycross, Bethany J ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (3 BUTOXY 4 METHOXYBENZYL) 2 IMIDAZOLIDINONE; AMRINONE; ETAZOLATE; LIPOPOLYSACCHARIDE; MILRINONE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL STRAIN L 929; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME INHIBITION; HEART LEFT VENTRICLE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALS; CYCLIC AMP; LIPOPOLYSACCHARIDES; MALE; MICE; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030431326     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. BAIM, D. S., MCDOWELL, A. V., CHERNILES, J., MONKAD, E. S., PARKER, J. A., EDELSON, J., BRAUNWALD, E. AND GROSSMAN, W.: Evaluation of a new bipyridine inotropic agent - milrinone - in patients with severe congestive heart failure. N. Engl. J. Med. 309: 748-756, 1983.
2. BEUTLER, B., HAN, J., KRUYS, V. AND GIROIR, B. P.: Coordinate regulation of TNF biosynthesis at the levels of transcription and translation. In Tumor Necrosis Factors: The Molecules and Their Emerging Role in Medicine, ed. by B. Beutler, pp. 561-574, Raven Press, New York, 1992.
3. BRADLEY, P., PRIEBAT, D., CHRISTENSEN, R. AND ROTHSTEIN, G.: Measurement of cutaneous inflammation: Estimation of neutrophils content with an enzyme marker. J. Invest. Dermatol. 78: 206-209, 1982.
4. CHALKIADAHS, G. E., KOSTAKIS, A., KARAYANNACOS, P. E., CHALKIADAHS, M. E., SGOUROMALI, S., GIAMARELLOU, H. AND SKALKEAS, G. D.: Pentoxifylline in the treatment of experimental peritonitis in rats. Arch. Surg. 120: 1141-1144, 1985.
5. COLUCCI, W. S., WRIGHT, R. F. AND BRAUNWALD, E.: New positive inotropic agents in the treatment of congestive heart failure (part I). N. Engl. J. Med. 314: 290-299, 1986.
6. DUTKA, D. P., ELBORN, J. S., DELAMERE, F., SHALE, D. J. AND MORRIS, G. K: Tumor necrosis factor in severe congestive cardiac failure. Br. Heart J. 70: 141-143, 1993.
7. FINKEL, M. S., ODDIS, C. V., JACOB, T. D., WATKINS, S. C., HATTLER, B. G. AND SIMMONS, R. L.: Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science (Wash. DC) 287: 387-389, 1992.
8. FISCHER, A. T., ERBEL, R. AND TREESE, N.: Current status of phosphodiesterase inhibitors in the treatment of congestive heart failure. Drugs 44: 928-945, 1992.
9. FOSTER, S. J. AND MCCORMICK, L. M.: Tumour necrosis factor production by rat blood and its ex vivo pharmacological modulation. Agents Action 39: C61-C63, 1995.
10. GARG, R., PACKER, M., PITT, B. AND YUSUF, S.: Heart failure in the 1990s: Evolution of a major public health problem in cardiovascular medicine. J. Am. Coll. Cardiol. 22: suppl. A, 3A-5A, 1993.
11. GIROIR, B. P. AND BEUTLER, B.: Effect of amrinone on tumor necrosis factor production in endotoxic shock. Circ. Shock 36: 200-207, 1992.
12. GIROIR, B. P., JOHNSON, J. H., BROWN, T., ALLEN, G. L. AND BEUTLER, B.: The tissue distribution of tumor necrosis factor biosynthesis during endotoxemia. J. Clin. Invest. 90: 693-698, 1992.
13. HAN, J., THOMPSON, P. AND BEUTLER, B.: Dexamethasone and pentoxifylline inhibit endotoxin-induced cachectin/tumor necrosis factor synthesis at separate points in the signaling pathway. J. Exp. Med. 2: 391-394, 1990.
14. HARRISON, S. A., CHANG, M. L. AND BRAVO, J. A.: Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs. Circulation 73: suppl. III, III109-III115, 1986.
15. HERSKOWITZ, A., CHOI, S., ANSARI, A. A. AND WESSELINGH, S.: Cytokine mRNA expression in postischemic/reperfused myocardium. Am. J. Pathol. 146: 419-128, 1995.
16. HO, K. K. L., PINSKY, J. L., KANNEL, W. B. AND LEVY, D.: The epidemiology of heart failure: The Framingham study. J. Am. Coll. Cardiol. 4: suppl. A, 6A-13A, 1993.
17. KARIA, T. AND DAGE, R. C.: Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesterase. Biochem. Pharmacol. 37: 3267-3270, 1988.
18. KONSTAM, M. A., COHEN, S. R., WEILAND, D. S., MARTIN, T. T., DAS, D., ISNER, J. M. AND SALEM, D. N.: Relative contribution of inotropic and vasodilator effects to amrinone-induced hemodynamic improvement in congestive heart failure. Am. J. Cardiol. 57: 242-248, 1986.
19. LEVINE, B., KALMAN, J., MAYER, L., FILLIT, H. M. AND PACKER, M.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med. 323: 236-241, 1990.
20. MATSUMORI, A., SHIOI, T., YAMADA, T., MATSUI, S. AND SASAYAMA, S.: Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation 89: 955-958, 1993.
21. MATTHEWS, N. AND NEALE, M. L.: Cytotoxicity assays for tumour necrosis factor and lymphotoxin. In Lymphotoxins and Interferons, ed. by M. J. Damens, A. G. Morris and A. J. H. Geaving, pp. 221-225, IRL Press, Washington, DC, 1987.
22. MCMURRAY, J., ABDULLAH, I., DARGIE, J. H. AND SHAPIRO, D.: Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br. Heart J. 66: 356-358, 1991.
23. MOLNAR-KIMBER, K., YONNO, L., HEASLIP, R. AND WEICHMAN, B.: Modulation of TNFα and IL-1β from endotoxin-stimulated monocytes by selective PDE isozyme inhibitors. Agents Action 39: C77-C79, 1993.
24. NAKAYAMA, D. K., GELLER, D. A., SILVIO, M. D., BLOOMGARDEN, G., DAVIS, P., PITT, B., HATAKEYAMA, K., KAGAMIYAMA, H., SIMMONS, R. L. AND BILLIAR, T. R.: Tetrahydrobiopterin synthesis and inducible nitric oxide production in pulmonary artery smooth muscle. Am. J. Physiol. 266: L455-L460, 1994.
25. NICHOLSON, C. D., CHALLISS, R. A. J. AND SHAHID, M.: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol. Sci. 12: 19-27, 1991.
26. NOEL, P., NELSON, S., BOKULIC, R., BAGBY, G., LIPPTON, H., LIPSCOMB, G. AND SUMMER, W.: Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci. 47: 1023-1029, 1995.
27. OKADA, F., NAGAO, S., HARADA, Y., XAVIER, R. M., NAKAMURA, M., ISHIDA, T. AND TANIGAWA, Y.: The role of cyclic AMP in the lipopolysaccharide-induced suppression of thymidine kinase activity in macrophages. Biochim. Biophys. Acta 1265: 201-208, 1995.
28. 2-stimulated cAMP accumulation by lipopolysaccharide in murine peritoneal macrophages. J. Biol. Chem. 266: 10305-10312, 1991.
29. PACKER, M.: The development of positive inotropic agents for chronic heart failure: How have we gone astray? J. Am. Coll. Cardiol. 22: suppl. A, 119A-126A, 1993.
30. PACKER, M.: Is tumor necrosis factor an important neurohormonal mechanism in chronic heart failure? Circulation 92: 1379-1382, 1995.
31. m cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582. J. Cardiovasc. Pharmacol. 24: 403-410, 1995.
32. PINSKY, D. J., CAI, B., RODRIGUEZ, C., SCIACCA, R. R. AND CANNON, P. J.: The lethal effects of cytokine-induced nitric oxide on cardiac myocytes are blocked by nitric oxide synthase antagonism or transforming growth factor. J. Clin. Invest. 95: 677-685, 1995.
33. PRABHAKAR, U., LIPSHUTZ, D., BARTUS, O., SLIVJAK, M. J., SMITH, E. F., III, LEE, J. C. AND ESSER, K. L.: Characterization of cAMP-dependent inhibition of LPS-induced TNF production by rolipram, a specific phosphodiesterase IV (PDE IV) inhibitor. Int. J. Immunopharmacol. 16: 805-816, 1994.
34. REEVES, M. L., LEIGH, B. K. AND ENGLAND, P. J.: The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle. Biochem. J. 241: 535-541, 1987.
35. REITHMANN, C., GIERSCHIK, P., WERDAN, K. AND JACOBS, K. H.: Tumor necrosis factor α up-regulates Giα and Giβ proteins and adenylyl cyclase responsiveness in rat cardiomyocytes. Eur. J. Pharmacol. 206: 53-60, 1991.
36. ROCCI, M. L., JR, AND WILSON, H.: The pharmacokinetics and pharmacodynamics of newer inotropic agents. Clin. Pharmacakinet. 13: 91-109, 1987.
37. SEMMLER, J., GEBERT, U., EISENHUT, T., MOELLER, J., SCHONHARTING, M. M., ALLERA, A. AND ENDRES, S.: Xanthine derivatives: Comparison between suppression of tumor necrosis factor-α production and inhibition of cAMP phosphodiesterase activity. Immunology 78: 520-525, 1993.
38. SEMMLER, J., WACHTEL, H. AND ENDRES, S.: The specific type IV phosphodiesterase inhibitor rolipram suppresses tumor necrosis factor-α production by human mononuclear cells. Int. J. Immunopharmacol. 15: 409-413, 1995.
39. SHAHID, M. AND NICHOLSON, C. D.: Comparison of cyclic nucleotide phosphodiesterase isoenzymes in rat and rabbit ventricular myocardium: Positive inotropic and phosphodiesterase inhibitory effects of ORG 30029, milrinone and rolipram. Naunyn-Schmiedeberg's Arch. Pharmacol. 342: 698-705, 1990.
40. SHAHID, M., WILSON, M., NICHOLSON, C. D. AND MARSHALL, R. J.: Species dependent differences in the properties of participate cyclic nucleotide phosphodiesterase from rat and rabbit ventricular myocardium. J. Pharm. Pharmacol. 42: 283-284, 1990.
41. SHAPIRA, L., TAKAHIBA, S., CHAMPAGNE, C., AMAR, S. AND VAN DYKE, T. E.: Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-α and IL-β production by human monocytes. J. Immunol. 153: 1818-1824, 1994.
42. SMITH, C. J., SUN, D., HOEGLER, C., ZHAO, G., XU, X. AND MOGGIO, R. A.: Reduced gene expression of the cyclic GMP-inhibited, cyclic AMP phosphodiesterase III in canine heart failure (Abstract). Circulation 90: I-425, 1994.
43. TRACEY, K J. AND CERAMI, A.: Tumor necrosis factor: A pleiotropic cytokine and therapeutic target. Annu. Rev. Med. 45: 491-503, 1994.
44. VITTONE, L., CHIAPPE, L. E., ARGEL, M. I., CINGOLANI, H. E. AND CHIAPPE, G. E.: The mechanical and biochemical effects of pentoxifylline on the perfused rat heart. Experientia (Basel) 36: 1088-1090, 1980.
45. WARD, A., BROGDEN, R. N., HEEL, R. C., SPEIGHT, T. M. AND AVERY, G. S.: Amrinone: A preliminary review of its pharmacological properties and therapeutic use. Drugs 26: 468-502, 1983.
46. WEISHAAR, R. E., KOBYLARZ-SINGER, D. C., STEFFEN, R. P. AND KAPLAN, H. R.: Subclasses of cyclic AMP-spedfic phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility. Circ. Res. 61: 539-547, 1987.
47. WIMSATT, D. K., HOHL, C. M., BRIERLEY, G. P. AND ALTSCHULD, R. A.: Calcium accumulation and release by the sarcoplasmic reticulum of digitonin-lysed adult mammalian ventricular cardiomyocytes. J. Biol. Chem. 265: 14849-14857, 1990.